M&A Deal Summary |
|
---|---|
Date | 2016-11-21 |
Target | Selexys Pharmaceuticals |
Sector | Life Science |
Buyer(s) | Novartis |
Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1996 |
Sector | Life Science |
Employees | 104,323 |
Revenue | 46.7B USD (2023) |
Novartis is a global healthcare and pharmaceutical enterprise dedicated to advancing medical innovation and enhancing patient well-being. Renowned for its pioneering research and development efforts, Novartis has a comprehensive portfolio encompassing groundbreaking pharmaceuticals, generic medications, biosimilars, and eye care solutions. Novartis was founded in 1996 and is based in Basel, Switzerland.
DEAL STATS | # |
---|---|
Overall | 13 of 32 |
Sector (Life Science) | 10 of 26 |
Type (Add-on Acquisition) | 11 of 28 |
State (Oklahoma) | 1 of 1 |
Country (United States) | 12 of 24 |
Year (2016) | 1 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2015-10-21 |
Admune Therapeutics
Danvers, Massachusetts, United States Admune Therapeutics LLC is a clinical stage biotechnology company. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-12-16 |
Ziarco Pharma
Sandwich, United Kingdom Ziarco Pharma Ltd. is a clinical stage biotechnology company, developing products to treat chronic inflammatory diseases with a focus on inflammatory skin disorders, in particular atopic dermatitis and psoriasis. |
Buy | - |